http://orcid.org/0000-0002-9532-5654 http://orcid.org/0000-0002-9532-5654 http://orcid.org/0000-0002-9532-5654
Figures & data
Figure 1. MRI scans of the patient before and after treatment for prostate cancer. (A–E) T1-weighted image (T1WI) and T2-weighted image (T2WI), as well as the sagittal view and lymph node images from T2WI from June 21, 2011 to April 13, 2017. Red arrows indicate the tumor in the prostate and lymph node metastasis.
Figure 2. Treatment regimen and laboratory test results during and after treatment for prostate cancer. (A) Therapeutic schedule. (B) Serum levels of TPSA, FPSA, and testosterone during and after treatment. FPSA, free prostate-specific antigen; TPSA, total prostate-specific antigen. ADT: Androgen deprivation therapy.
Figure 3. (A) BRCA2 mutation in patient with prostate cancer and esophageal squamous carcinoma. (B) Diagram of wild type (WT) Citation(ref. 37) and mutant BRCA2 proteins, as predicted from cDNA and genomic sequencing. NLS, nuclear localization signal; TR2, RAD51-binding domain.
Figure 4. Immunohistochemistry and western blot analysis of tumor tissues. (A) The patient's prostate and esophageal tumor tissues were stained with antibodies against BRCA (C-terminus and N-terminus) and compared with the corresponding control tumor tissues. HE, hematoxylin and eosin. (B) The patient's esophageal tumor tissues kept in liquid nitrogen were collected, lysed and then analyzed with western blot assays with specific antibodies against BRCA2 N-terminus.
Table 1. The levels of TPSA, FPSA and testosterone of the patient during the treatment.